- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04184934
Optimal Clinical Predictors to AKI in Cirrhotic Patients Experienced Acute Gastrointestinal Hemorrhage (ABC(AKI-B))
Optimal Clinical Predictors to Acute Kidney Injury in Cirrhotic Patients Experienced Acute Gastrointestinal Hemorrhage
Study Overview
Status
Detailed Description
Specific aims of this study :
- To examine the influences of acute gastrointestinal hemorrhage on the serological or urinary level of novel renal biomarkers in patients with cirrhosis.
- To investigate the ability of novel biomarkers to predict the development of acute kidney injury and the response to renal salvage treatment in patients with cirrhosis suffering from acute gastrointestinal hemorrhage.
- To investigate the ability of novel biomarkers to differentiate the precipitating factors (such as sepsis-induced AKI, hypervolemia-induced AKI, etc.) and the causes of AKI between pre-renal AKI, acute tubular necrosis, and hepatorenal syndrome.
- To investigate the ability of these novel biomarkers to predict the hepatic and overall outcomes in patients with cirrhosis suffering from acute gastrointestinal hemorrhage.
Estimation of sample size :
According to previous studies, the estimated incidence of AKI in cirrhotic patients suffering from gastrointestinal hemorrhage is about 10-15%. The type 1 error is set as 0.05; and the type 2 error is set as 0.2. Then, the calculated sample size is about 80. Considering the possibility of loss of follow-up is about 10%, the estimated sample size will be about 90 patients.
Sample collection and laboratory experiments:
Patients will be prospectively followed from admission until discharge.
- Sample collection: A fresh 30-mL of urine sample will be collected either by way of clean catch or Foley catheter tubing will be collected at the time in admission to our hospital, at the peak stage of AKI, and after the recovery (if recovery occurs) 10cc of blood will be collected from the peripheral vessel once at the time in admission to our hospital, at the peak stage of AKI, and after the recovery (if recovery occurs).
- Abdominal sonography (including evaluation of bilateral kidneys) will be arranged if no image study available within 3 months upon admission.
Urine examination:
urinary neutrophil gelatinase-associated lipocalin (NGAL), IL-18, spot urine protein, albumin, creatinine, urea nitrogen, sodium, kidney injury molecule 1 (KIM-1), liver-type fatty acid binding protein (L-FABP), insulin-like growth factor, and tissue inhibitor metalloproteinase will be measured.
Serum examination:
serum NGAL, cystatin C, blood urea nitrogen, creatinine, uric acid, IL-1, tumor necrosis factor alfa will be measured.
Record clinical information and regular follow-up:
Record any precipitating factors, including: presence of active infection or sepsis, the dosage and types of diuretics, presence of acute hemorrhage, the frequency and the drainage volume of each therapeutic paracentesis, supplement of albumin or other colloid fluid, presence of heart failure or active pulmonary problems, prescription of non-selective beta blockers, non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, herbs and other nephrotoxic drugs, as well as others. Record any chronic underlying diseases, including: diabetes mellitus, hypertension, congestive heart failure (the baseline left ventricular ejection rate if available), chronic kidney disease (baseline glomerular filtration rate), autoimmune disease, anemia of chronic disorder, the severity of liver diseases (such as status of ascites, serum albumin level, presence of varices, etc.), and so on.
Regular follow-up of renal function and fluid status at least twice per week as the routine management in clinical practice. Regular measurements of patients' clinical data, including vital signs will be done in daily practice.
Detailed laboratory methods:
Urine samples will be immediately refrigerated and then centrifuged at 5,000g for 10 minutes at -4°C. Aliquots of 1 mL of supernatant will be subsequently stored within 6 hours of collection in cryovials at -80°C for NGAL, IL-18, KIM-1, L-FABP, albumin, sodium, and creatinine measurements. No additives or protease inhibitors will be used. All biomarkers will be measured from frozen aliquots that will not undergo any additional freeze-thaw cycles. Laboratory measurements will be performed by personnel blinded to patient information.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 11217
- Recruiting
- Taipei Veterans General Hospital, Taiwan
-
Contact:
- Ming-Chih Hou, MD
- Phone Number: 7506 886-2-28712121
- Email: mchou@vghtpe.gov.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Consecutive adult cirrhotic patients admitted to Taipei Veterans General Hospital for suffering from acute gastrointestinal hemorrhage without intervention within 3 days
Exclusion Criteria:
- Patients less than 20 years old.
- Patients with antecedent or ongoing active malignancy.
- Patients with human immunodeficiency virus coinfection or severe comorbidities, such as end-stage renal disease or uremia without regular dialysis, recent acute coronary syndrome or stroke, severe heart failure, severe arrhythmia, and major trauma.
- Patients with severe hyperbilirubinemia with total bilirubin > 10mg/dL.
- Patients who underwent trans-jugular intrahepatic portosystemic shunt.
- Patients who are pregnant or breastfeeding.
- Patients who refuse to join the study.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality
Time Frame: 6 weeks
|
Inpatient mortality rate
|
6 weeks
|
Incidence rates of AKI
Time Frame: 6 weeks
|
Incidence rates of AKI in patient suffering from acute gastrointestinal hemorrhage
|
6 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-07-044BC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Cirrhosis
-
Postgraduate Institute of Medical Education and...Society for the Study of Liver Diseases, Chandigarh ( India )UnknownDecompensated Cirrhosis of LiverIndia
-
SUUMC Central Military Hospital Dr Carol DavilaRecruiting
-
The Cleveland ClinicRecruiting
-
The Cleveland ClinicRecruitingCirrhosis, LiverUnited States
-
University of PittsburghNational Institute on Drug Abuse (NIDA)CompletedCirrhosis, LiverUnited States
-
Beth Israel Deaconess Medical CenterAmerican Association for the Study of Liver Diseases FoundationCompleted
-
Asian Institute of Gastroenterology, IndiaCompletedCirrhosis, LiverIndia
-
Sherief Abd-ElsalamUnknown
-
Fundació Institut de Recerca de l'Hospital de la...Spanish Clinical Research Network - SCReNWithdrawn